Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics


Salarius Pharmaceuticals Inc (SLRX): $0.21

0.00 (1.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SLRX POWR Grades


  • SLRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 68.43% of US stocks.
  • SLRX's strongest trending metric is Value; it's been moving down over the last 76 days.
  • SLRX's current lowest rank is in the Momentum metric (where it is better than 4.14% of US stocks).

SLRX Stock Summary

  • The ratio of debt to operating expenses for Salarius Pharmaceuticals Inc is higher than it is for about merely 0.5% of US stocks.
  • With a year-over-year growth in debt of -100%, Salarius Pharmaceuticals Inc's debt growth rate surpasses only 0% of about US stocks.
  • Revenue growth over the past 12 months for Salarius Pharmaceuticals Inc comes in at -64.84%, a number that bests only 2.24% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to SLRX, based on their financial statements, market capitalization, and price volatility, are SLS, MNDO, PULM, SINT, and PZG.
  • Visit SLRX's SEC page to see the company's official filings. To visit the company's web site, go to www.salariuspharma.com.

SLRX Valuation Summary

  • SLRX's price/sales ratio is 9.9; this is 12.78% lower than that of the median Healthcare stock.
  • SLRX's price/sales ratio has moved NA NA over the prior 80 months.
  • SLRX's price/sales ratio has moved NA NA over the prior 80 months.

Below are key valuation metrics over time for SLRX.

Stock Date P/S P/B P/E EV/EBIT
SLRX 2021-08-31 9.9 1.0 -5.3 -1.6
SLRX 2021-08-30 9.5 1.0 -5.1 -1.4
SLRX 2021-08-27 9.5 1.0 -5.1 -1.4
SLRX 2021-08-26 9.6 1.0 -5.1 -1.4
SLRX 2021-08-25 9.5 1.0 -5.1 -1.4
SLRX 2021-08-24 9.0 0.9 -4.8 -1.1

SLRX Growth Metrics

    Its 5 year cash and equivalents growth rate is now at -82.18%.
  • The 3 year price growth rate now stands at -95.19%.
  • The 2 year cash and equivalents growth rate now stands at -56.3%.
SLRX's revenue has moved up $1,075,679 over the prior 34 months.

The table below shows SLRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.840216 -10.2002 -12.76824
2021-09-30 3.319138 -8.853078 -10.82732
2021-06-30 4.697377 -10.02412 -8.806852
2021-03-31 5.3693 -9.326119 -7.516741
2020-12-31 5.233301 -10.31136 -7.748661
2020-09-30 4.793072 -11.57444 -7.467527

SLRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SLRX has a Quality Grade of D, ranking ahead of 5.25% of graded US stocks.
  • SLRX's asset turnover comes in at 0.129 -- ranking 239th of 682 Pharmaceutical Products stocks.
  • XTNT, CPRX, and BMY are the stocks whose asset turnover ratios are most correlated with SLRX.

The table below shows SLRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.129 1.000 -2.587
2021-03-31 0.183 1.000 -2.888
2020-12-31 0.242 1.000 -4.816
2020-09-30 0.254 1.000 -15.428
2020-06-30 0.256 1.000 9.857
2020-03-31 0.231 0.989 6.965

SLRX Price Target

For more insight on analysts targets of SLRX, see our SLRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.43 Average Broker Recommendation 1.33 (Strong Buy)

SLRX Stock Price Chart Interactive Chart >

Price chart for SLRX

SLRX Price/Volume Stats

Current price $0.21 52-week high $1.20
Prev. close $0.21 52-week low $0.16
Day low $0.20 Volume 1,188,800
Day high $0.23 Avg. volume 802,692
50-day MA $0.20 Dividend yield N/A
200-day MA $0.51 Market Cap 11.93M

Salarius Pharmaceuticals Inc (SLRX) Company Bio


Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.


SLRX Latest News Stream


Event/Time News Detail
Loading, please wait...

SLRX Latest Social Stream


Loading social stream, please wait...

View Full SLRX Social Stream

Latest SLRX News From Around the Web

Below are the latest news stories about Salarius Pharmaceuticals Inc that investors may wish to consider to help them evaluate SLRX as an investment opportunity.

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference

HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will present during the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference on Thursday, February 24, 2022. During the presentation, Mr. Arthur will highlight Salarius’ busi

Yahoo | February 17, 2022

Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on February 24, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty five

Yahoo | February 15, 2022

Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will deliver a virtual presentation at the 2022 BIO CEO & Investor Conference. The event is taking place February 14-17, 2022, at the New York Marriott Marquis as a hybrid conference that allows vir

Yahoo | February 8, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Dr. Santiesteban will lead the development of SP-3164 and other targeted protein degradation assetsHOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company’s new targeted protein degradation program. In this newly created position, Dr

Yahoo | February 3, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Happy Friday, trader!

William White on InvestorPlace | January 14, 2022

Read More 'SLRX' Stories Here

SLRX Price Returns

1-mo 13.57%
3-mo -49.47%
6-mo -59.57%
1-year -80.56%
3-year -98.42%
5-year -99.78%
YTD -57.63%
2021 -45.54%
2020 -75.93%
2019 -54.18%
2018 -90.54%
2017 -33.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5968 seconds.